1984-32-3

Basic information

• Product Name: N-Hydroxy-p-bromobenzenesulfonamide
• Synonyms: N-Hydroxy-p-bromobenzenesulfonamide
• CAS NO: 1984-32-3
• Molecular Formula: C₆H₆BrNO₃S
• Molecular Weight: 252.09
• Mol File: 1984-32-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 394.1°C at 760 mmHg
• Flash Point: 192.2°C
• Appearance: /
• Density: 1.837g/cm³
• Vapor Pressure: 6.42E-07mmHg at 25°C
• Refractive Index: 1.624
• CAS DataBase Reference: N-Hydroxy-p-bromobenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-Hydroxy-p-bromobenzenesulfonamide(1984-32-3)
• EPA Substance Registry System: N-Hydroxy-p-bromobenzenesulfonamide(1984-32-3)

Safety Data

• Hazardous Substances Data: 1984-32-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H6BrNO3S/c7-5-1-3-6(4-2-5)12(10,11)8-9/h1-4,8-9H

Upstream product

• 98-58-8 4-bromobenzenesulfonyl chloride 

Downstream Products

• 75732-35-3 N-(p-bromobenzenesulfonyl)-N,O-bis(trimethylsilyl)hydroxylamine 

Relevant articles and documents

Piloty's acid derivative with improved nitroxyl-releasing characteristics

Recent studies have shown that nitroxyl (HNO) (1HNO/ 3NO-), which is the one-electron-reduced form of nitric oxide (NO), has unique biological activities, especially in the cardiovascular system, and HNO-releasing agents may have therapeutic potential. Since few HNO donors are available for use under physiological conditions, we synthesized and evaluated a series of Piloty's acid (PA) derivatives and evaluated their HNO-releasing activity under physiological conditions. N-Hydroxy-2- nitrobenzenesulfonamide (17) was the most efficient HNO donor among our synthesized PA derivatives, including the lead compound, 2-bromo-N- hydroxybenzenesulfonamide (2). The high HNO-releasing activity is suggested to be due to electronic and steric effects. Compound 17 may be a useful tool for biological experiments.

N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.